40 results about "Blood coagulation factor XIII" patented technology

The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.

The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients.

Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and / or inducer(s) within the mixture, favoring fibrin clot formation.

The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and / or prophylaxis of bleeding disorders, in particular hemophilia A and / or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.

The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein C inhibitor, and the use thereof for treating bleeding episodes.

The present invention relates to blood coagulation factor XIII (FXIII) for treatment and / or prevention of an infection by a microorganism and / or the symptoms associated with said infection, a pharmaceutical composition comprising a pharmaceutically effective amount of said FXIII, a method for the manufacture of a medicament comprising a pharmaceutically effective amount of said FXIII, and a method of treatment comprising administering to a patient in need a pharmaceutically effective amount of said FXIII.

The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and / or of fibrinogen in deficiency states is possible.

The invention provides a human plasma with multiple functions and a preparation method thereof, including general-purpose plasma and blood component additives; the general-purpose plasma is general-type fresh frozen plasma or general-purpose freeze-dried plasma; the blood component additive is selected from albumin, C Globulins, platelets, fibrinogen, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, and prothrombin complex any one or more of them. The advantages are: for patients who need to supplement plasma and at least one blood component additive at the same time, only the plasma including the corresponding blood component additive needs to be transfused, thereby increasing the scope and flexibility of use, saving the patient's blood transfusion time, and saving Blood transfusion equipment.

The invention provides a preparation method for fibrinogen with the advantages of high dissolution rate in the production process, short production period, fast solubility in clinical use, good biological activity, high safety in clinical use and high yield. An aid is added into supernate anticoagulant plasma. Compared with the prior art, the preparation method has the advantages that: 1, the preparation method provided by the invention is high in extraction efficiency; 2, the aid adopted in the method can improve the quality of the fibrinogen product, and plays a role in protecting the biological activities of the fibrinogen and blood coagulation factors XIII in virus inactivation and cold ethanol settlement processes; 3, in the process, the process solubility time of the fibrinogen is shortened to about 10 minutes; and 4, the solubility time of the freeze dried product of the fibrinogen is within 30 seconds, so precious time is won for rescuing patients in time in clinic.

The present invention relates to prophylactic dosing regimens with long-acting factor IX (FIX) in dosing intervals of 1 week or longer, including (but not limited to) 10 days or longer, such as two weeks, three weeks or even monthly.

A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.

Described herein are RPE cells engineered to secrete FVII proteins, as well as compositions, pharmaceutical formulations, and implantable devices comprising these engineered RPE cells, and methods of making and using them for treating patients suffering from hemophilia or FVII deficiency.

The present invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia.

The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).

The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.

This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.

The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.

By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and / or prophylactic agent for diseases caused by thrombus formation.

Disclosed herein are methods of treating subjects with hemophilia and low bone mineral density (BMD) with a chimeric protein comprising a coagulation factor and a Fc domain. In certain embodiments, the chimeric protein is rFVIIIFc. In certain embodiments, a subject to be treated has hemophilia A.